Results 191 to 200 of about 554,154 (221)
Some of the next articles are maybe not open access.

Platelets and Antiphospholipid Antibodies

Lupus, 1996
The involvement of platelets in the antiphospholipid syndrome is complex and the full pathogenic significance is not fully understood. The binding of aPL antibodies to the platelet membrane may result in the thrombopenia and further haemostatic activation.
openaire   +2 more sources

Antiphospholipid Antibodies

JCR: Journal of Clinical Rheumatology, 1997
Although significant progress has been made during the last decade in our knowledge of the antiphospholipid antibodies (aPL), there are two major questions in clinical practice that require further guidelines: Indications for aPL determination and laboratory tests to choose. This article reviews the main clinical indications to search for aPL (systemic
R, Cervera, J, Font, R A, Asherson
openaire   +2 more sources

Antiphospholipid antibodies and malignancies

Autoimmunity Reviews, 2010
Since the 1980s it is known that an important thrombogenic mechanism is mediated by antiphospholipid antibodies (aPL). Aim of this review is to discuss how much aPL presence may worsen the thrombophilic state of neoplastic patients and how much cancer may worsen and extend the thrombophilic state of patients with Antiphospholipid Syndrome (APS). In the
TINCANI, Angela   +2 more
openaire   +3 more sources

Noncriteria antiphospholipid antibodies in antiphospholipid syndrome

International Journal of Laboratory Hematology
AbstractAntiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombotic manifestations and/or obstetric complications in patients with persistently positive antiphospholipid antibodies (aPL). aPL are a heterogeneous group of autoantibodies, but only lupus anticoagulant, anticardiolipin (aCL), and antibeta2‐glycoprotein I antibodies
openaire   +2 more sources

Antiphospholipid Antibodies in Children

Seminars in Thrombosis and Hemostasis, 1998
Lupus anticoagulant (LA) is made up of heterogeneous IgG and IgM antibodies that prolong clotting times in vitro and is associated with an increased rate of both thrombosis and hemorrhage in vivo, although thrombosis is far more common. Many mechanisms of action have been explored, but none explains the coagulation abnormality of every sample tested ...
openaire   +2 more sources

Antiphospholipid antibody and antiphospholipid antibody syndrome.

Current opinion in rheumatology, 1992
Over the past year, many reports have been published on a variety of clinical manifestations related to antiphospholipid antibodies. The low prevalence of anticardiolipin antibodies with the rare occurrence of thrombosis and a low rate of fetal loss in studies in Malaysia and China showed a potential role for local factors.
openaire   +1 more source

Antiphospholipid Antibody Syndromes

Rheumatic Disease Clinics of North America, 1989
There is no doubt that in some individuals the presence of antibodies to negatively charged phospholipids currently measured as the lupus anticoagulant, a biologically false positive VDRL, and anticardiolipin antibodies is associated with certain clinical features, in particular, a predisposition to both arterial and venous thrombosis and, in women, to
openaire   +2 more sources

Antibody–Drug Conjugates: Smart Chemotherapy Delivery Across Tumor Histologies

Ca-A Cancer Journal for Clinicians, 2022
Shanu Modi   +2 more
exaly  

Non-Criteria Antiphospholipid Antibodies in Antiphospholipid Syndrome: Diagnostic Value Added

Frontiers in Immunology, 2022
Feng Sun, Jianping Guo, Hongjiang Liu
exaly  

ANTIPHOSPHOLIPID ANTIBODIES

British Journal of Haematology, 1990
openaire   +2 more sources

Home - About - Disclaimer - Privacy